Filter byLast updatedSelectAfterBeforeFrom - ToDateEnd DateCategoryHumanTopicCOVID-19MedicinesVaccinesAdvanced therapiesAntimicrobial resistanceBiologicalsBiosimilarsBrexitCareersClinical trialsCompassionate useCompliance and inspectionsCorporateData on medicinesEarly accessFeesGeneric and hybrid medicinesGovernanceInnovationMaximum residue limitMedication errorMedicines for use outside the EUMedicine shortagesMpoxPaediatricsParallel distributionPharmacovigilanceProcurementProduct informationQuality of medicinesRare diseasesReferralsRegulatory and procedural guidanceResearch and developmentScientific adviceScientific guidelinesSMEVeterinary limited marketsDiseases areaViral diseasesCancerCardiovascular diseasesDiabetesHIV and AIDSImmune-system diseasesNeurodegenerative diseasesTreatment of human immunodeficiency virus type 1 (HIV-1) infectionResponsible bodyCHMPCATCMDhCOMPCVMPHMPCManagement BoardPDCOPRACPatient safetyYesFiltersResults (1) BimervaxSort byLast update date (new to old)Last update date (old to new)A-ZZ-AEMA recommends approval of Bimervax as a COVID-19 booster vaccine30 March 2023NewsHumanCOVID-19MedicinesVaccines
EMA recommends approval of Bimervax as a COVID-19 booster vaccine30 March 2023NewsHumanCOVID-19MedicinesVaccines